In a report released yesterday, Michael Okunewitch from Maxim Group maintained a Buy rating on BioRestorative Therapies (BRTX – Research Report), with a price target of $6.00. The company’s shares opened today at $3.96.
Okunewitch covers the Healthcare sector, focusing on stocks such as Kiora Pharmaceuticals, Citius Pharmaceuticals, and BioRestorative Therapies. According to TipRanks, Okunewitch has an average return of -19.5% and a 39.58% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioRestorative Therapies with a $6.00 average price target.
See today’s best-performing stocks on TipRanks >>
BRTX market cap is currently $14.92M and has a P/E ratio of -0.76.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Biorestorative Therapies Inc. provides stem cell collections, storage, and treatment services. It intends to develop a laboratory, performing cellular characterization and culturing, therapeutic outcomes analysis, stem cell-related IP and stem cell collection and storage services. The company is developing the following scientific initiatives: brtxDISC Program offers a non-surgical treatment for bulging and herniated discs and addresses the gap between non-invasive and invasive back procedures. The ThermoStem Program focuses on treatments for metabolic disorders and obesity and uses brown fat stem cells, which initial research indicates increased caloric burning and reduced glucose and lipid levels in the body. It also offers plant stem cell-based facial creams and products under the Stem Pearls brand. Biorestorative Therapies was founded on June 13, 1997 and is headquartered in Melville, NY.
Read More on BRTX:
- BioRestorative completes enrollment for safety run-in of Phase 2 BRTX-100 study
- BioRestorative Therapies Announces Completion of Patient Enrollment for Safety Run-In Component of its Phase 2 Clinical Study of BRTX-100
- BioRestorative Therapies to seek FDA approval to expand BRTX-100 application
- BioRestorative Therapies to Seek FDA Approval to Expand the Clinical Application of BRTX-100
- BioRestorative Therapies to Participate at the 35th Annual ROTH MKM Conference on March 12 -14, 2023
